3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fluorouracil
72
Leucovorin
71
Oxaliplatin
47
Irinotecan
31
Capecitabine
24
Bevacizumab
23
Folfox protocol
20
Cetuximab
15
Chemotherapy, Adjuvant
13
Celecoxib
7
Aspirin
6
Laparoscopy
5
XELOX
4
Panitumumab
4
Neoadjuvant Therapy
4
Levamisole
4
dehydroftorafur
3
Tegafur
3
Surgical Procedures, Operative
3
Observation
3
Floxuridine
3
vatalanib
2
tislelizumab
2
pertuzumab
2
encorafenib
2
atezolizumab
2
Trastuzumab
2
Standard of Care
2
Semaxinib
2
Selenium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Colonic Neoplasms
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn